11 June 2024 in Tuberk Toraks
: Immune responses against Coronavirus (SARS-CoV-2) may be highly complex. It has been suggested that T-cell fatigue develops due to continuous stimulation of T-cells by SARS-CoV-2 in Coronavirus disease-2019 (COVID-19). It was aimed to assess peripheral lymphocyte subsets and T-cell exhaustion in various clinical courses of the disease in patients diagnosed with COVID-19. This study included 150 patients who were assigned into the "mild-to-moderate disease" group, or "severe disease" group based on their clinical and laboratory characteristics. Peripheral lymphocyte subsets and T-cell exhaustion markers [programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (Tim-3)] were determined in the peripheral blood using flow cytometry. Mean (±SD) age was 53.3 ± 14.5 years, and female to male ratio was 55/95. In the mild-to-moderate disease (MMD) group, 55 patients had pneumonia and 20 patients had COVID-19 without pneumonia. In the severe disease (SD) group, 43 patients had severe pneumoniae and 32 patients were in critical condition. Lymphocyte counts were less than 1.0 x 109/L in 69.3% of the patients in the SD group, and the difference between the MMD group and SD group was statistically significant (p= 0.001). Total T cells, CD4+ and CD8+ T-cell counts were significantly lower in the SD group vs. MMD group (p< 0.001, p< 0.001, p< 0.001, respectively). PD-1 expression by CD8+ and CD4 T+ cells was higher (p= 0.042, p= 0.029, respectively) and Tim-3 expression from CD4 T+ cells was lower (p= 0.000) in the SD group vs. MMD group. Serum IFN-γ levels were not statistically different in the MMD and SD groups (p= 0.2). T-cell counts may be significantly reduced along with an increased expression of the T-cell exhaustion marker PD-1 in severe COVID-19, but Tim-3 expression was not increased in our study patients.
3 September 2023 in The European Research Journal
Objectives: The present study evaluates the prevalence of monosensitization and polysensitization in patients with pollen-hypersensitive moderate-to-severe persistent allergic rhinitis (AR), and determines the clinical characteristics of the two phenotypes. Methods: This retrospective cohort study included 160 patients with moderate-to-severe persistent AR among the 3,699 patients who presented to allergy outpatient clinics who were found to have hypersensitivity to pollen based on a skin prick test and/or allergen-specific IgE positivity. The patients were divided into two groups: monosensitized (hypersensitivity to pollen alone), and polysensitized (hypersensitivity to pollen and other allergens). Both groups were evaluated for allergen hypersensitivity, symptoms of AR, symptom frequency and comorbidities related to AR. Results: Of the 160 patients, 83 (51.9%) were monosensitized and 77 (48.1%) were polysensitized. The mean age was 29.5 ± 10.7 yeasrs and 28.3 ± 8.3 years, respectively and the female-to-male ratio was 42/41 and 47/30 in the two groups. Nasal congestion was remarkably more common in the polysensitized patients than in the monosensitized patients (p = 0.01). Hypersensitivity to weed mix and Cupressus arizonica pollen identified with a skin prick test was significantly more common in the polysensitized patients than in the monosensitized patients (p = 0.03 and p = 0.01, respectively). The two groups were similar in terms of the prevalence of asthma and other comorbidities related to rhinitis (p = 0.78). Conclusions: In this single-center study, the rates of monosensitization and polysensitization were found to be similar in patients with pollen-hypersensitive moderate-to-severe AR, and the clinical characteristics of the polysensitized phenotype were different from those of the monosensitized phenotype.